Lifecare ASA

Lifecare appoints renowned metabolic expert Prof. Simon Dankel as Principal Investigator for upcoming clinical trial

Bergen, Norway, 27 May 2025 -- Lifecare ASA (LIFE), a medtech company

developing next-generation Continuous Glucose Monitoring (CGM) technology, is

pleased to announce that Professor Simon Nitter Dankel has been appointed as

Principal Investigator for its upcoming clinical trial.

Prof. Dankel is a leading expert in metabolic diseases and nutritional

biochemistry, with an impressive track record of high-impact research and

leadership in clinical trials. He currently heads the Research Unit for Health

Surveys (RUHS) at the University of Bergen, which will host the first trial

site.

RUHS brings extensive experience in executing clinical and decentralized

trials and offers state-of-the-art infrastructure including a metabolic

kitchen, biobank collaboration, and GDPR-compliant digital systems for

participant management. This partnership sets the stage for robust,

high-quality data collection and world-class regulatory standards.

This appointment follows Lifecare's recent filing for regulatory approval to

launch the clinical trial of its innovative CGM implant, marking another key

milestone toward CE-marking and commercial launch.

"Engaging Prof. Dankel and RUHS is a strategic move that highlights our

commitment to scientific excellence and clinical rigor," said Joacim Holter,

CEO of Lifecare ASA. "Their expertise will be instrumental as we accelerate

efforts to bring our transformative technology to people living with

diabetes."

About us

Lifecare ASA is a medical sensor company developing technology for sensing and

monitoring of various body analytes. Lifecare's focus is to bring the next

generation of Continuous Glucose Monitoring ("CGM") systems to market.

Lifecare enables osmotic pressure as sensing principle. Lifecare's sensor

technology is suitable for identifying and monitoring the occurrence of a wide

range of analytes and molecules in the human body and in pets.

Contacts

For further information, please contact:

Joacim Holter, CEO, [email protected], +47 40 05 90 40

Renete Kaarvik, CFO, [email protected], +47 94 83 82 42

AI Terminal